A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study. Findings will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021, and are included in the ASCO press program.